AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 73
- Registration Number
- NCT03593785
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Lynparza Breast Cancer Clinical Experience Investigation
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 111
- Registration Number
- NCT03590938
- Locations
- 🇯🇵
Research Site, Yamaguchi, Japan
FASENRA SCEI for Long-term Use
Completed
- Conditions
- Asthma
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 653
- Registration Number
- NCT03588546
- Locations
- 🇯🇵
Research Site, Yamaguchi, Japan
ALEXANDRIA Study Egypt
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 436
- Registration Number
- NCT03583463
- Locations
- 🇪🇬
Research Site, Zagazig, Egypt
A Prospective Cohort Study of Asthma and COPD Overlap in Japanese COPD Patients Using the Diagnostic Criteria of The Japanese Respiratory Society
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2018-07-05
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 710
- Registration Number
- NCT03577795
- Locations
- 🇯🇵
Tohoku University School of Medicine, Sendai, Miyagi, Japan
A Ph 1 Study of Epanova® in Healthy Chineses
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT03574142
- Locations
- 🇨🇳
Research Site, Beijing, China
Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).
Completed
- Conditions
- NSCLC (Non-small Cell Lung Cancer)
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2020-06-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 268
- Registration Number
- NCT03562819
- Locations
- 🇮🇳
Research Site, Kolkata, West Bengal, India
🇮🇳Reserch Site, Punjab, Chandigarh, India
S-CEI of Nexium in Paediatric Patients
Completed
- Conditions
- Peptic Ulcer, Gastroesophageal Reflux
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT03562026
- Locations
- 🇯🇵
Research Site, Yamagata, Japan
Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Biological: Benralizumab
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 598
- Registration Number
- NCT03557307
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Development of AECOPD Identification Tool (DETECT Study)
Completed
- Conditions
- Acute Exacerbations of COPD
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT03556475
- Locations
- 🇨🇳
Research Site, Xinxiang, China
© Copyright 2025. All Rights Reserved by MedPath